# Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

> **NCT05333302** · PHASE1 · RECRUITING · sponsor: **Belarusian Research Center for Pediatric Oncology, Hematology and Immunology** · enrollment: 10 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- Lymphoblastic B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CD19 CAR-T-cells
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05333302
- **Lead sponsor:** Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-26
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05333302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05333302, "Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05333302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*